Looking Forward to ISGIDAR 2026, Register NOW!

ISGIDAR 2026, our next meeting that will be held in conjunction with the 2026 CPDD meeting in Portland, Oregon on June 13th, 2026. We are looking forward to an excellent lineup of speakers and seeing you all there!

REGISTRATION

You may register for the 2026 ISGIDAR meeting through the CPDD meeting registration when it opens. Registration fees this year are $150 for regular members and $50 for trainees. Find more about CPDD here.

TRAVEL AWARDS

This year, ISGIDAR will sponsor two competitive travel awards, the ISGIDAR Travel Award and the William Woolverton Memorial Travel Award, for trainees to present a paper at the ISGIDAR meeting on Saturday, June 13th. Awardees will receive funds to help defray the cost of travel to the ISGIDAR meeting.  Those who do not receive the award, but who receive good reviews will be encouraged to present their papers at the ISGIDAR meeting.

SUBMISSION DEADLINE: April 7, 2026 

ELIGIBILITY: Currently a post-baccalaureate, graduate student, or post-doctoral fellow.

PAPER SUBMISSION: Electronic submissions are required (Microsoft word, or less desirable, a pdf). Submit a short paper (maximum of 1500 words, not including references, and a single figure) describing your study (Abstract, Introduction, Methods, Results, Discussion, with the Abstract limited to 200 words) to Drew Townsend (drew.townsend@nih.gov). Pilot projects with few subjects also are acceptable, if the findings are interesting.  The scope of the paper should be consistent with a 20-min slide presentation. Please include paper title, name, mailing address, email, and phone number. 

ISGIDAR 2026 CALL FOR PRESENTATIONS

This is a call for presentations (original research, mini-symposia, and “favorite paper” reviews) for the annual ISGIDAR meeting on Saturday, June 13th. You can register for the meeting through the CPDD website: (Registration Link). All submissions will be podium presentations and should be sent to Greg Collins (collinsg@umich.edu).

SUBMISSION DEADLINE FOR PAPERS AND SYMPOSIA: May 1, 2026

ORIGINAL RESEARCH SUBMISSIONS: For those wishing to make an original research presentation, please submit 1) a title of the talk, 2) a list of all authors, and 3) a brief (2-3 sentence) description of the talk. Though all topics are welcome, we are particularly interested in research using rodents, non-human primates, or human subjects to investigate the reinforcing effects of drugs in the context of polysubstance use.

MINI-SYMPOSIA SUBMISSIONS: For those wishing to submit a mini-symposium, please send 1) a title of the symposium, 2) a brief (2-3 sentence) description, and 3) a list of the individual speakers and titles of their talks.

“FAVORITE PAPER” REVIEW SUBMISSIONS: To encourage participation by those individuals who might not have new drug self-administration data to share (especially trainees!), and to highlight those seminal publications that shaped our careers, we are offering the opportunity for review presentations of “favorite papers”. Please submit 1) the citation and 2) a brief (2-3 sentence) description of the paper. 

NEWSLETTER

Hear more about the goings on of ISGIDAR in the annual newsletter below!

Look forward to seeing everyone in 2026!

image1

REMINDER: If you have updated contact information or know of colleagues who have recently moved, please assist us in forwarding this information on and encouraging them to reach out to us with their new contact information!

ISGIDAR always welcomes TAX-DEDUCTIBLE CONTRIBUTIONS. If you would like to make a tax-deductible contribution go to https://squareup.com/store/isgidarcom

Note: Our content management system occasionally places third-party advertisements on this website. ISGIDAR does not receive income from these advertisements and does not endorse their content.

ISGIDAR CPDD Meeting 2025!

June 13, 2026
3 months to go.

Mission

The mission of ISGIDAR is to promote interest in, and to facilitate the dissemination of, new information related to drugs as reinforcers, especially as it may relate to human drug abuse.